Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. PR Newswire LONDON, October 28, 2013 LONDON, October 28, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The U.S. equity market edged higher on Friday, October 25, 2013. The S&P 500 ended the day at 1,759.77, up 0.44%; the Dow Jones Industrial Average closed at 15,570.28, up 0.39%; and the NASDAQ Composite finished at 3,943.36, up 0.37%. Shares in the Biotechnology industry ended on a mixed note, even as the broader market posted gains. The major movers in the industry included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Sequenom Inc. (NASDAQ: SQNM), Nektar Therapeutics (NASDAQ: NKTR), and Discovery Laboratories Inc. (NASDAQ: DSCO). AAAResearchReports.com has completed their technical analysis on INO, SQNM, NKTR, and DSCO and these free reports are accessible by registering at: http://www.aaaresearchreports.com/register/ Shares in Inovio Pharmaceuticals Inc. ended the day 1.01% higher at $2.00, after oscillating between $1.97 and $2.02 during Friday's session. A total of 1.48 million shares were traded, which is significantly below the daily average volume of 9.22 million. Inovio Pharmaceuticals Inc.'s stock has surged 38.89% in the previous three months, outperforming the S&P 500, which has gained 4.03% during the same period. Further, the company's shares are trading above their 200-day moving average of $1.13. Sign up for free technical research on INO at: http://www.AAAResearchReports.com/INO102813.pdf On Friday, Sequenom Inc.'s stock advanced to close at $2.34, up 0.86% from the previous day's closing price of $2.32. The company's shares vacillated between $2.30 and $2.38 during the trading session. A total of 1.80 million shares were traded, which is below the daily average volume of 3.47 million. The company's shares have gained 1.30% in the previous three trading sessions, outperforming the S&P 500, which has gained 0.29% during the same period. However, Sequenom Inc.'s stock is trading below its 50-day and 200-day moving averages of $2.75 and $3.74, respectively. Be sure to read our latest technical research on SQNM by registering at: http://www.AAAResearchReports.com/SQNM102813.pdf Nektar Therapeutics' stock plummeted by 3.08% to $10.39, after oscillating between $10.27 and $10.75 during Friday's trading session. A total of 0.67 million shares were traded, which is below the daily average volume of 1.36 million. The company's stock has fallen by 0.95% in the previous three trading sessions, underperforming the S&P 500, which has gained 0.29% during the same period. Moreover, Nektar Therapeutics' stock is trading below its 50-day and 200-day moving averages of $11.73 and $10.69, respectively. Sign up and read the complimentary report on NKTR at: http://www.AAAResearchReports.com/NKTR102813.pdf Shares in Discovery Laboratories Inc. fell by 0.85% on Friday, even as the broader market posted gains. The company's shares closed the day at $2.32, after trading between $2.27 and $2.35. A total of 0.41 million shares were traded, which is below the daily average volume of 0.68 million. Despite Friday's losses, the company's shares have surged 16.58% in the last one month and 42.33% in the previous three months, outperforming the S&P 500, which has advanced 4.02% and 4.03% during the respective periods. Furthermore, Discovery Laboratories Inc.'s stock is trading above its 50-day and 200-day moving averages of $2.04 and $1.98, respectively. The free report on DSCO can be downloaded by signing up now at: http://www.AAAResearchReports.com/DSCO102813.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126, Contact Name: Peter F. Jones, Email ID: firstname.lastname@example.org
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.
Press spacebar to pause and continue. Press esc to stop.